Bluejay Diagnostics, Inc. (NASDAQ:BJDX) Short Interest Update

Posted by Latisha Jones on Jul 1st, 2024

Bluejay Diagnostics, Inc. (NASDAQ:BJDX – Get Free Report) was the target of a large decrease in short interest in June. As of June 15th, there was short interest totalling 15,000 shares, a decrease of 23.1% from the May 31st total of 19,500 shares. Based on an average trading volume of 48,700 shares, the days-to-cover ratio is currently 0.3 days. Currently, 3.2% of the company’s stock are short sold.

Bluejay Diagnostics Stock Performance

Shares of NASDAQ BJDX traded down $0.01 during midday trading on Monday, hitting $0.69. 849,455 shares of the stock traded hands, compared to its average volume of 108,939. Bluejay Diagnostics has a one year low of $0.64 and a one year high of $111.84. The firm has a 50-day moving average of $3.90 and a two-hundred day moving average of $6.83. The firm has a market capitalization of $234,634.00, a P/E ratio of -0.01 and a beta of 0.83.

Bluejay Diagnostics (NASDAQ:BJDX – Get Free Report) last issued its quarterly earnings results on Thursday, March 28th. The company reported ($14.24) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($5.44) by ($8.80).

Institutional Investors Weigh In On Bluejay Diagnostics

A hedge fund recently bought a new stake in Bluejay Diagnostics stock. Armistice Capital LLC purchased a new position in Bluejay Diagnostics, Inc. (NASDAQ:BJDX – Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 24,230 shares of the company’s stock, valued at approximately $30,000. Armistice Capital LLC owned approximately 1.95% of Bluejay Diagnostics as of its most recent filing with the Securities and Exchange Commission. 18.47% of the stock is owned by institutional investors.

About Bluejay Diagnostics

(Get Free Report)

Bluejay Diagnostics, Inc, a medical diagnostic company, develops rapid test for the monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge, which includes reagents and components.